Abstract: A spark gap device includes an optional insulating layer formed on a substrate, a metal layer formed on a surface of the insulating layer, a solder resist layer formed on a surface of the metal layer, and first and second contacts. The metal layer includes a central portion and a peripheral portion separated by an air gap that surrounds the central portion of the metal layer and exposes the insulating layer. The solder resist layer includes a central portion disposed on the central portion of the metal layer having a first opening exposing a central region of the central portion of the metal layer, and a peripheral portion disposed on the peripheral portion of the metal layer having a second opening exposing a peripheral region of the peripheral portion of the metal layer. The first contact is formed in the first opening and the second contact is formed in the second opening.

Abstract: A spark gap device includes an optional insulating layer formed on a substrate, a metal layer formed on a surface of the insulating layer, a solder resist layer formed on a surface of the metal layer, and first and second contacts. The metal layer includes a central portion and a peripheral portion separated by an air gap that surrounds the central portion of the metal layer and exposes the insulating layer. The solder resist layer includes a central portion disposed on the central portion of the metal layer having a first opening exposing a central region of the central portion of the metal layer, and a peripheral portion disposed on the peripheral portion of the metal layer having a second opening exposing a peripheral region of the peripheral portion of the metal layer. The first contact is formed in the first opening and the second contact is formed in the second opening.

Abstract: Two new polymorphic forms of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid tris(hydroxymethyl)methylammonium salt (1), processes for making them and their use in the production of a pharmaceutical useful in the treatment of, inter alia, hypercholesterolemia, hyperlipoproteinemia and atherosclerosis are described.

Abstract: Human myelin basic protein (h-MBP) has a molecular weight of 18.5 KD and contains 170 amino acid residues. Synthetic peptides ranging in length from about 8 to 25 residues and covering the entire length of the protein have been produced. Antibodies to h-MBP (anti-MBP) were found to be neutralized by the synthetic peptides, in vitro, which span the h-MBP from about amino acid residue 61 to about amino acid residue 106. The peptides, which cover both the amino (about residues 1 to 63) and carboxy (about residues 117 to 162) terminals of h-MBP did not neutralize purified anti-MBP. Intrathecal administratin of peptide MBP(75-95), MBP(86-95), or MBP(82-98) produced complete binding-neutralization of free (F) anti-MBP with no change in bound (B) levels. A control peptide MBP35-58 had no effect on F or B anti-MBP levels. Intravenous administration of MBP(75-95), MBP(86-95), or MBP(82-98) resulted in significant decline of F and B CSF anti-MBP levels.

Abstract: Human myelin basic protein (h-MBP) has a molecular weight of 18.5 KD and contains 170 amino acid residues. Synthetic peptides ranging in length from about 8 to 25 residues and covering the entire length of the protein have been produced. Antibodies to h-MBP (anti-MBP) were found to be neutralized by the synthetic peptides, in vitro, which span the h-MBP from about amino acid residue 61 to about amino acid residue 106. The peptides, which cover both the amino (about residues 1 to 63) and carboxy (about residues 117 to 162) terminals of h-MBP did not neutralize purified anti-MBP. Intrathecal administratin of peptide MBP(75-95), MBP(86-95), or MBP(82-98) produced complete binding-neutralization of free (F) anti-MBP with no change in bound (B) levels. A control peptide MBP35-58 had no effect on F or B anti-MBP levels. Intravenous administration of MBP(75-95), MBP(86-95), or MBP(82-98) resulted in significant decline of F and B CSF anti-MBP levels.